Developer docs
API playgroundTry for free, no card

Search company profiles

Sapient

Full company profile

uuid00002y2

Namestring
Sapient
Legal namestring
Sapient Bioanalytics, LLC
Websiteurl
sapient.bio
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Sapient (legally Sapient Bioanalytics, LLC) is a San Diego-based contract research organization founded in 2020 that provides multi-omics biomarker discovery services to accelerate drug development. The company operates a mass spectrometry-centric platform spanning discovery and targeted proteomics, metabolomics, lipidomics, and cytokine profiling, complemented by the DynamiQ Insights Engine — a population-scale molecular-clinical database of more than 67,000 pre-characterized human plasma samples linked to electronic health record data (demographics, diagnosis, medications, clinical outcomes). Sapient serves pharmaceutical and biotechnology companies as its primary customer segment, with secondary segments in academic medical centers and precision medicine platforms, and engages clients through a consultative, science-led direct sales motion (no self-serve or channel distribution).

Sapient's technical differentiators include proprietary rapid LC-MS (rLC-MS) metabolomics workflows capable of capturing more than 15,000 metabolites and lipids per sample at throughput of over 2,000 samples per day; next-generation FFPE proteomics measuring more than 10,000 protein groups in archival tissue; the Tumor Protein Mapping Platform with four workflows (SurfaceSeek, SignalingSeek, ImmuneSeek, ResistanceSeek) for functional tumor biology; and Certified Service Provider status for Alamar Biosciences' NULISA platform, which provides attomolar-level cytokine detection across inflammation (250+ biomarkers) and CNS disease (220+ biomarkers) panels. Reported analytical performance metrics include a median coefficient of variation below 12% across matrices.

Sapient generates revenue through professional services (fee-for-service CRO engagements) priced via project-specific quotes, with multi-year contract cadences, pilot study options, and pricing varying by study type, sample count, matrix, and analytical depth. The company has received approximately $13.8 million in non-dilutive funding from the Bill & Melinda Gates Foundation across 2020 and 2022 to support biomarker research for nutritional and disease-related interventions. Its go-to-market is content- and thought-leadership-driven, emphasizing scientific publications, webinars, conference participation (including AACR 2026), and case studies to reach pharma/biotech decision-makers.

Short descriptiontext

Sapient is a San Diego-based multi-omics CRO providing mass spectrometry-based proteomics, metabolomics, lipidomics, and cytokine profiling services to pharmaceutical, biotechnology, academic, and precision medicine clients for biomarker discovery and drug development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biomarker discovery services, multi-omics profiling, proteomics services, metabolomics analysis, cytokine profiling
Industry4 codes
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Multi-Omics Biomarker Discovery Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Multi-Omics CRO Services
TypeProfessional Services
Description

Sapient operates as a Contract Research Organization (CRO) providing fee-for-service biomarker discovery and validation studies. Revenue is generated through project-based engagements for proteomics, metabolomics, lipidomics, and cytokine profiling services. Studies are priced based on experimental design complexity, sample count, assay types, and analytical depth. The company offers both discovery (broad profiling) and targeted (quantitative validation) services with pricing varying by scope and requirements.

sapient.bio
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1Project-based CRO pricing - custom quotes for each study
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available. Services are offered through 'Request a Study', 'Book a Meeting', and 'Let's Talk' CTAs. Pricing varies based on study type (discovery vs. targeted), number of samples, matrix types, analytical depth, and whether DynamiQ contextualization is included. Pilot studies are available.

sapient.bio
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1DynamiQ
Description

Molecular-clinical database and insights engine for biomarker validation and biological contextualization.

sapient.bio
+5 more records
Core offering1 text field

Sapient operates as a Contract Research Organization (CRO) providing fee-for-service multi-omics biomarker discovery and validation studies. The core offering combines mass spectrometry-based proteomics, metabolomics, lipidomics, and NULISA cytokine profiling with the DynamiQ™ Insights Engine — a population-scale molecular-clinical database of over 67,000 pre-characterized human plasma samples used for biological contextualization, preclinical translation, target identification, and virtual experiments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 12,000+ proteins measured in tissue/tumor samples
+5 more records
Product overview1 text field

Sapient (Sapient Bioanalytics) is a multi-omics biomarker discovery CRO offering a unified platform of laboratory services centered on mass spectrometry-based proteomics and metabolomics, complemented by NULISA cytokine profiling technology. The core offering consists of Discovery Proteomics and Targeted Protein Assays (powered by a >12K protein menu), Discovery Metabolomics & Lipidomics (via proprietary rLC-MS capturing >15K metabolites per sample), and NULISAseq cytokine panels (250+ inflammation markers, 220+ CNS disease markers). The DynamiQ Insights Engine serves as the data platform, providing cross-validation against a database of >67,000 pre-characterized plasma samples. Tumor-specific workflows include SurfaceSeek, SignalingSeek, ImmuneSeek, and ResistanceSeek under the Tumor Protein Mapping Platform. All services integrate through study design collaboration and biocomputational analysis for decision-ready insights.

Product and service12 records
1DynamiQ Insights Engine
CategoryData Platform
Description

Population-scale molecular-clinical database platform with over 67,000 pre-characterized human plasma samples linked to multi-omics data and matched EHR data (demographics, diagnosis, medications, clinical outcomes). Enables biological contextualization, preclinical translation, target identification, and virtual experiments for pharma and biotech researchers.

2Discovery Proteomics Services
CategoryProteomics Services
Description

Label-free DIA workflows with advanced protein extraction delivering 12,000+ protein groups in tissue/tumors, 10,000+ in FFPE samples, 5,400+ in plasma, 6,000+ in saliva, and 3,600+ in CSF. Median CV <12% across matrices. For pharma, biotech, and academic researchers.

3Targeted Protein Assays
CategoryProteomics Services
Description

High-sensitivity quantitative protein measures leveraging labeled peptides for direct absolute quantitation of predefined proteins of interest, including PTMs and proteoforms. Menu of more than 12,000 off-the-shelf assays. For drug development researchers.

4Discovery Metabolomics & Lipidomics Services
CategoryMetabolomics Services
Description

Proprietary rapid LC-MS (rLC-MS) systems capturing more than 15,000 metabolites and lipids per sample in a single run with throughput to analyze over 2,000 samples per day. In-house library of more than 13,000 reference standards for metabolite identification. For pharma and biotech researchers.

5Target Metabolite & Lipid Panels
CategoryMetabolomics Services
Description

Ready-to-order targeted panels including Amino Acids Panel (47 amino acids), Fatty Acids Panel (34 fatty acids), Phospholipids Panel (170 phospholipids), Triglycerides Panel (161 triacylglycerides), and additional panels for diglycerides, FAHFAs, inflammatory markers, metabolic dysregulation, and VLCDCAs.

6Metabolite Identification Services
CategoryMetabolomics Services
Description

High-confidence metabolite identification using in-house library of more than 13,000 chemical reference standards, enabling MSI Tier 1 identification for up to 1,400 metabolites. Database of over 6 million MS2 spectra for putative structural identification of unannotated molecules.

7NULISAseq Inflammation Panels
CategoryCytokine Profiling
Description

Ultra-sensitive cytokine profiling of 250+ biomarkers of inflammation and immune response with attomolar-level detection (fg/mL) and up to 12 logs of dynamic range. Provided as Certified Service Provider for Alamar Biosciences' NULISA platform.

8NULISAseq CNS Disease Panels
CategoryCytokine Profiling
Description

Multiplexed analyses of 220+ biomarkers of neurodegenerative disease including neuro-specific proteins with attomolar sensitivity on the ARGO HT System. For researchers developing CNS and neurodegeneration therapeutics.

9NULISAqpcr Assays
CategoryCytokine Profiling
Description

Low- and single-plex assays for absolute quantitation including BD-pTau217 single-plex assay and AD 5-plex assay covering APOE4, BD-pTau217, Aβ42, GFAP, and NfL for Alzheimer's Disease assessment.

10Tumor Protein Mapping Platform
CategoryTumor Proteomics
Description

Suite of mass spectrometry-based discovery proteomics workflows quantifying functional tumor biology across four dimensions: cell surface proteome (SurfaceSeek), phosphoproteomics (SignalingSeek), tumor immune microenvironment (ImmuneSeek), and resistance mechanisms (ResistanceSeek). Optimized for fresh-frozen and FFPE human tumor tissue. For oncology researchers and drug developers.

11Multi-Omics Studies
CategoryIntegrated Multi-Omics
Description

Integrated omics services combining proteomics, metabolomics, lipidomics, cytokine profiling, and DNA/RNA sequencing to build comprehensive mechanistic insight from regulation through downstream functional outcomes.

12Biocomputational Analysis
CategoryData Analysis
Description

Multi-scale analyses including expert integration of molecular, phenotypic, and clinical data; integrated multi-omics analyses from regression analysis to ML-based modeling; and DynamiQ-powered biological contextualization to deliver decision-ready findings.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or Integration
Description

Sapient is a Certified Service Provider for Alamar Biosciences' NULISA platform. The company has been formally trained and validated on the NULISA technology and its associated ARGO™ HT System, which is housed on-site in Sapient's laboratory. This enables ultra-sensitive detection of cytokines, chemokines, and neuroinflammatory mediators.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Metabolon is a global leader in metabolomics services with a large proprietary reference library, comparable to Sapient's rLC-MS metabolomics platform and 13,000+ reference standards. Both compete for metabolomics-led biomarker discovery projects in pharma, nutrition, and academic research.

TypeDirect peer
Description

Seer is a proteomics company developing its own deep proteome platform and reference database for biomarker discovery, conceptually similar to Sapient's DynamiQ + DIA proteomics strategy. Both companies are pursuing the vision of population-scale proteomic data as a differentiator.

TypeDirect peer
Description

Biognosys is a Swiss proteomics CRO offering discovery and targeted mass spectrometry-based proteomics services similar to Sapient's DIA workflows. Both compete for pharma biomarker discovery programs and emphasize deep proteome coverage with quantitative robustness.

TypeEmerging player
Description

Alamar Biosciences is the developer of the NULISA platform that Sapient runs as a Certified Service Provider. While primarily a technology provider rather than a CRO, Alamar's evolving service-provider network and direct assay offerings overlap with Sapient's NULISAseq service business.

TypeBroad incumbent
Description

Eurofins is a global life sciences testing services conglomerate offering biomarker, proteomics, and clinical diagnostics services at far greater scale. While not specialized in multi-omics biomarker discovery, it competes for large pharma outsourced laboratory budgets.

TypeDirect peer
Description

Standard BioTools (formerly Fluidigm) operates a multi-omics proteomics and cytometry franchise serving translational research customers. While its core platform is mass cytometry-based, it competes with Sapient in biomarker discovery workflows serving academic and pharma translational pipelines.

7Caprion Biosciences
TypeDirect peer
Description

Caprion is a specialty CRO offering mass spectrometry-based proteomics and immune monitoring services for pharma and biotech, directly comparable to Sapient's targeted protein assays and tumor profiling workflows.

TypeBroad incumbent
Description

Labcorp (including its Covance drug development CRO and central laboratory services) is a broad incumbent offering biomarker testing, companion diagnostics, and clinical trial lab services. It competes for enterprise biomarker budgets but lacks Sapient's depth in deep multi-omics discovery.

TypeEmerging player
Description

Nautilus is developing a single-molecule protein analysis platform aimed at deep proteome profiling. While its technology is distinct from Sapient's mass spectrometry approach, it targets the same biomarker discovery market with a similar promise of broad proteome coverage.

TypeDirect peer
Description

Olink is a direct peer in protein biomarker discovery, offering proximity extension assay (PEA)-based multiplexed proteomics for pharma and academic customers. Sapient's DIA proteomics and Olink's antibody-based panels compete for the same biomarker discovery budgets in pharma translational research.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sapient

Multi-Omics Biomarker Discovery Servicessapient.bio

Sapient is a San Diego-based multi-omics CRO providing mass spectrometry-based proteomics, metabolomics, lipidomics, and cytokine profiling services to pharmaceutical, biotechnology, academic, and precision medicine clients for biomarker discovery and drug development.

What Sapient does

Sapient (legally Sapient Bioanalytics, LLC) is a San Diego-based contract research organization founded in 2020 that provides multi-omics biomarker discovery services to accelerate drug development. The company operates a mass spectrometry-centric platform spanning discovery and targeted proteomics, metabolomics, lipidomics, and cytokine profiling, complemented by the DynamiQ Insights Engine — a population-scale molecular-clinical database of more than 67,000 pre-characterized human plasma samples linked to electronic health record data (demographics, diagnosis, medications, clinical outcomes). Sapient serves pharmaceutical and biotechnology companies as its primary customer segment, with secondary segments in academic medical centers and precision medicine platforms, and engages clients through a consultative, science-led direct sales motion (no self-serve or channel distribution).

Sapient's technical differentiators include proprietary rapid LC-MS (rLC-MS) metabolomics workflows capable of capturing more than 15,000 metabolites and lipids per sample at throughput of over 2,000 samples per day; next-generation FFPE proteomics measuring more than 10,000 protein groups in archival tissue; the Tumor Protein Mapping Platform with four workflows (SurfaceSeek, SignalingSeek, ImmuneSeek, ResistanceSeek) for functional tumor biology; and Certified Service Provider status for Alamar Biosciences' NULISA platform, which provides attomolar-level cytokine detection across inflammation (250+ biomarkers) and CNS disease (220+ biomarkers) panels. Reported analytical performance metrics include a median coefficient of variation below 12% across matrices.

Sapient generates revenue through professional services (fee-for-service CRO engagements) priced via project-specific quotes, with multi-year contract cadences, pilot study options, and pricing varying by study type, sample count, matrix, and analytical depth. The company has received approximately $13.8 million in non-dilutive funding from the Bill & Melinda Gates Foundation across 2020 and 2022 to support biomarker research for nutritional and disease-related interventions. Its go-to-market is content- and thought-leadership-driven, emphasizing scientific publications, webinars, conference participation (including AACR 2026), and case studies to reach pharma/biotech decision-makers.

Sapient firmographics

Firmographics
Name
Sapient
Legal name
Sapient Bioanalytics, LLC
Website
https://sapient.bio
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Sapient is a San Diego-based multi-omics CRO providing mass spectrometry-based proteomics, metabolomics, lipidomics, and cytokine profiling services to pharmaceutical, biotechnology, academic, and precision medicine clients for biomarker discovery and drug development.
Ownership category
akta.pro rank

Sapient industry classification

Industry
Product category
Multi-Omics Biomarker Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAB
Proteomics & Mass Spectrometry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAA
Biomarker Discovery & Validation (omics, assay feasibility, clinical validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Biomarker discovery services
  • Multi-omics profiling
  • Proteomics services
  • Metabolomics analysis
  • Cytokine profiling

Where Sapient is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Sapient business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Multi-Omics CRO Services: Sapient operates as a Contract Research Organization (CRO) providing fee-for-service biomarker discovery and validation studies. Revenue is generated through project-based engagements for proteomics, metabolomics, lipidomics, and cytokine profiling services. Studies are priced based on experimental design complexity, sample count, assay types, and analytical depth. The company offers both discovery (broad profiling) and targeted (quantitative validation) services with pricing varying by scope and requirements.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based CRO pricing - custom quotes for each study

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Sapient product offering

Product offering

Core offering

Sapient operates as a Contract Research Organization (CRO) providing fee-for-service multi-omics biomarker discovery and validation studies. The core offering combines mass spectrometry-based proteomics, metabolomics, lipidomics, and NULISA cytokine profiling with the DynamiQ™ Insights Engine — a population-scale molecular-clinical database of over 67,000 pre-characterized human plasma samples used for biological contextualization, preclinical translation, target identification, and virtual experiments.

Product overview

Sapient (Sapient Bioanalytics) is a multi-omics biomarker discovery CRO offering a unified platform of laboratory services centered on mass spectrometry-based proteomics and metabolomics, complemented by NULISA cytokine profiling technology. The core offering consists of Discovery Proteomics and Targeted Protein Assays (powered by a >12K protein menu), Discovery Metabolomics & Lipidomics (via proprietary rLC-MS capturing >15K metabolites per sample), and NULISAseq cytokine panels (250+ inflammation markers, 220+ CNS disease markers). The DynamiQ Insights Engine serves as the data platform, providing cross-validation against a database of >67,000 pre-characterized plasma samples. Tumor-specific workflows include SurfaceSeek, SignalingSeek, ImmuneSeek, and ResistanceSeek under the Tumor Protein Mapping Platform. All services integrate through study design collaboration and biocomputational analysis for decision-ready insights.

Differentiator

Problem solved

Functional benefit

Brands

  • DynamiQ: Molecular-clinical database and insights engine for biomarker validation and biological contextualization.
  • NULISAseq
  • SurfaceSeek
  • SignalingSeek
  • ImmuneSeek
  • ResistanceSeek

Products and services

  • DynamiQ Insights Engine Population-scale molecular-clinical database platform with over 67,000 pre-characterized human plasma samples linked to multi-omics data and matched EHR data (demographics, diagnosis, medications, clinical outcomes). Enables biological contextualization, preclinical translation, target identification, and virtual experiments for pharma and biotech researchers.
  • Discovery Proteomics Services Label-free DIA workflows with advanced protein extraction delivering 12,000+ protein groups in tissue/tumors, 10,000+ in FFPE samples, 5,400+ in plasma, 6,000+ in saliva, and 3,600+ in CSF. Median CV <12% across matrices. For pharma, biotech, and academic researchers.
  • Targeted Protein Assays High-sensitivity quantitative protein measures leveraging labeled peptides for direct absolute quantitation of predefined proteins of interest, including PTMs and proteoforms. Menu of more than 12,000 off-the-shelf assays. For drug development researchers.
  • Discovery Metabolomics & Lipidomics Services Proprietary rapid LC-MS (rLC-MS) systems capturing more than 15,000 metabolites and lipids per sample in a single run with throughput to analyze over 2,000 samples per day. In-house library of more than 13,000 reference standards for metabolite identification. For pharma and biotech researchers.
  • Target Metabolite & Lipid Panels Ready-to-order targeted panels including Amino Acids Panel (47 amino acids), Fatty Acids Panel (34 fatty acids), Phospholipids Panel (170 phospholipids), Triglycerides Panel (161 triacylglycerides), and additional panels for diglycerides, FAHFAs, inflammatory markers, metabolic dysregulation, and VLCDCAs.
  • Metabolite Identification Services High-confidence metabolite identification using in-house library of more than 13,000 chemical reference standards, enabling MSI Tier 1 identification for up to 1,400 metabolites. Database of over 6 million MS2 spectra for putative structural identification of unannotated molecules.
  • NULISAseq Inflammation Panels Ultra-sensitive cytokine profiling of 250+ biomarkers of inflammation and immune response with attomolar-level detection (fg/mL) and up to 12 logs of dynamic range. Provided as Certified Service Provider for Alamar Biosciences' NULISA platform.
  • NULISAseq CNS Disease Panels Multiplexed analyses of 220+ biomarkers of neurodegenerative disease including neuro-specific proteins with attomolar sensitivity on the ARGO HT System. For researchers developing CNS and neurodegeneration therapeutics.
  • NULISAqpcr Assays Low- and single-plex assays for absolute quantitation including BD-pTau217 single-plex assay and AD 5-plex assay covering APOE4, BD-pTau217, Aβ42, GFAP, and NfL for Alzheimer's Disease assessment.
  • Tumor Protein Mapping Platform Suite of mass spectrometry-based discovery proteomics workflows quantifying functional tumor biology across four dimensions: cell surface proteome (SurfaceSeek), phosphoproteomics (SignalingSeek), tumor immune microenvironment (ImmuneSeek), and resistance mechanisms (ResistanceSeek). Optimized for fresh-frozen and FFPE human tumor tissue. For oncology researchers and drug developers.
  • Multi-Omics Studies Integrated omics services combining proteomics, metabolomics, lipidomics, cytokine profiling, and DNA/RNA sequencing to build comprehensive mechanistic insight from regulation through downstream functional outcomes.
  • Biocomputational Analysis Multi-scale analyses including expert integration of molecular, phenotypic, and clinical data; integrated multi-omics analyses from regression analysis to ML-based modeling; and DynamiQ-powered biological contextualization to deliver decision-ready findings.

Quantifiable outcome

  • 12,000+ proteins measured in tissue/tumor samples
  • +5 more outcomes

Companies that use Sapient

Customer profile

Segments3 records

Ideal customer profiles3 records

Sapient technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

Sapient partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Alamar BiosciencescoreTechnology or IntegrationSapient is a Certified Service Provider for Alamar Biosciences' NULISA platform. The company has been formally trained and validated on the NULISA technology and its associated ARGO™ HT System, which is housed on-site in Sapient's laboratory. This enables ultra-sensitive detection of cytokines, chemokines, and neuroinflammatory mediators.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Sapient competitors and assessment

Company assessment

Direct peers

  • Metabolon: Metabolon is a global leader in metabolomics services with a large proprietary reference library, comparable to Sapient's rLC-MS metabolomics platform and 13,000+ reference standards. Both compete for metabolomics-led biomarker discovery projects in pharma, nutrition, and academic research.
  • Seer: Seer is a proteomics company developing its own deep proteome platform and reference database for biomarker discovery, conceptually similar to Sapient's DynamiQ + DIA proteomics strategy. Both companies are pursuing the vision of population-scale proteomic data as a differentiator.
  • Biognosys: Biognosys is a Swiss proteomics CRO offering discovery and targeted mass spectrometry-based proteomics services similar to Sapient's DIA workflows. Both compete for pharma biomarker discovery programs and emphasize deep proteome coverage with quantitative robustness.
  • Standard BioTools: Standard BioTools (formerly Fluidigm) operates a multi-omics proteomics and cytometry franchise serving translational research customers. While its core platform is mass cytometry-based, it competes with Sapient in biomarker discovery workflows serving academic and pharma translational pipelines.
  • Caprion Biosciences: Caprion is a specialty CRO offering mass spectrometry-based proteomics and immune monitoring services for pharma and biotech, directly comparable to Sapient's targeted protein assays and tumor profiling workflows.
  • Olink Holding (Olink Proteomics): Olink is a direct peer in protein biomarker discovery, offering proximity extension assay (PEA)-based multiplexed proteomics for pharma and academic customers. Sapient's DIA proteomics and Olink's antibody-based panels compete for the same biomarker discovery budgets in pharma translational research.

Emerging players

  • Alamar Biosciences: Alamar Biosciences is the developer of the NULISA platform that Sapient runs as a Certified Service Provider. While primarily a technology provider rather than a CRO, Alamar's evolving service-provider network and direct assay offerings overlap with Sapient's NULISAseq service business.
  • Nautilus Biotechnology: Nautilus is developing a single-molecule protein analysis platform aimed at deep proteome profiling. While its technology is distinct from Sapient's mass spectrometry approach, it targets the same biomarker discovery market with a similar promise of broad proteome coverage.

Broad incumbents

  • Eurofins Scientific: Eurofins is a global life sciences testing services conglomerate offering biomarker, proteomics, and clinical diagnostics services at far greater scale. While not specialized in multi-omics biomarker discovery, it competes for large pharma outsourced laboratory budgets.
  • Labcorp: Labcorp (including its Covance drug development CRO and central laboratory services) is a broad incumbent offering biomarker testing, companion diagnostics, and clinical trial lab services. It competes for enterprise biomarker budgets but lacks Sapient's depth in deep multi-omics discovery.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sapient social profiles

Digital presence

Sapient financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sapient leadership team

Management profile

Number of profiles

Profiles5 records

Sapient funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sapient M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sapient

What does Sapient do?

Sapient operates as a Contract Research Organization (CRO) providing fee-for-service multi-omics biomarker discovery and validation studies. The core offering combines mass spectrometry-based proteomics, metabolomics, lipidomics, and NULISA cytokine profiling with the DynamiQ™ Insights Engine — a population-scale molecular-clinical database of over 67,000 pre-characterized human plasma samples used for biological contextualization, preclinical translation, target identification, and virtual experiments.

Is Sapient a public or private company?

Sapient is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Sapient founded?

Sapient was founded in 2020. It employs 11 to 50 people.

Where is Sapient based?

Sapient is headquartered in San Diego, United States, in the North America region.

How does Sapient make money?

One revenue line is on record: multi-Omics CRO Services.

Who are Sapient's main competitors?

Direct peers on record are Metabolon, Seer, Biognosys, Standard BioTools, Caprion Biosciences and Olink Holding (Olink Proteomics). Emerging players are Alamar Biosciences and Nautilus Biotechnology. Broad incumbents are Eurofins Scientific and Labcorp.

Does Sapient have an API?

No public API is recorded for Sapient.

What industry is Sapient in?

Sapient's product category is Multi-Omics Biomarker Discovery Services. Its primary akta.pro industry code is HLAGANAB, Proteomics & Mass Spectrometry Services, with a secondary code of HLAAAMAA, Biomarker Discovery & Validation (omics, assay feasibility, clinical validation). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceSapient Launches Tumor Protein Mapping Platform to Characterize Functional Biology Across Critical Dimensions in Human TumorsSapient launched its Tumor Protein Mapping Platform, a suite of mass spectrometry-based proteomics workflows for tumor biology. The platform includes SurfaceSeek, SignalingSeek, ImmuneSeek, and ResistanceSeek, available for fresh-frozen and FFPE samples. It aims to provide direct protein-level characterization of tumor biology for drug development.Business Wire BlogSapient Launches Tumor Protein Mapping Platform to Characterize Functional Biology Across Critical Dimensions in Human TumorsSapient launched a tumor protein mapping platform with four mass spectrometry-based workflows—SurfaceSeek, SignalingSeek, ImmuneSeek, and ResistanceSeek—to map functional tumor biology across druggable surface proteins, signaling, immune, and resistance dimensions. The workflows work on both fresh-frozen and FFPE human tumor samples, enabling retrospective analysis of archived tissue.PR NewswireSapient Perception Secures €2M to Advance 10K Sensor Systems for Mission-Critical UAV OperationsDanish startup Sapient Perception ApS has raised a €2M pre-seed round co-led by Balnord and FORWARD.one to develop software-defined 10K sensor systems for UAVs that provide 100 times larger coverage than conventional sensors. The company will use the funding to grow its engineering team and support initial deployments with customers in defense, security, and emergency response industries. Sapient Perception is already partnered with Dropla Tech to integrate its sensors into UAVs used by the Ukrainian Ministry of Defence for detecting ambush drones and landmines along supply routes near front lines.SapientMulti-Omics Services for Dynamic Biomarker DiscoverySapient is promoting its multi-omics services, which include high-throughput metabolomics, lipidomics, proteomics, and cytokine assays for biomarker discovery. The company highlights its capability to process over 5,000 samples per day using next-generation mass spectrometry systems with extensive reference libraries.The ScientistSapient Partners with Rancho BioSciences to Accelerate the Next Generation of its Human Biology DatabaseSapient has partnered with Rancho BioSciences to enhance its Human Biology Database, which includes extensive biomarker data from over 100,000 human biosamples. The collaboration aims to expand the database's infrastructure, facilitating the integration of additional multi-omics and real-world data. This alliance is intended to improve data analysis speed and depth, supporting drug development efforts.SapientUniversity of Oxford Publishes Findings from Study Supported by SapientResearchers at the University of Oxford published findings in Lancet Diabetes & Endocrinology identifying lipid metabolite patterns linked to fetal growth trajectories and childhood health. Sapient provided mass spectrometry-based metabolomics analysis of over 3,500 samples from the INTERBIO-21st Study, supported by a Gates Foundation grant. The lipid signatures may serve as biomarkers for maternal-fetal metabolic or immunological differences.SapientSapient & Cedars-Sinai Collaboration on Immune Response StudySapient and Cedars-Sinai are collaborating on immune response research for COVID-19 and autoimmune diseases. A study published in JAMA Network Open found that 56% of adults with new Omicron antibodies were unaware of recent infection, suggesting low awareness may drive rapid transmission. The partnership aims to use Sapient's technologies for biomarker discovery.SapientSapient Receives $9.2M Grant for Population-Scale Discovery Mass Spectrometry AnalysisSapient has been awarded a $9.2 million grant from the Bill & Melinda Gates Foundation to conduct population-scale discovery metabolomics analysis using its rLC-MS platforms. The funding will support studies aimed at identifying biomarkers for nutritional and disease-prevention interventions, particularly for maternal and child health in developing countries. This grant extends prior collaborations where Sapient provided bioanalytical capacity and biocomputational support for global health projects.SapientSapient Featured in Bruker PR using timsTOF for Biomarker DiscoverySapient's proprietary rapid LC-MS technology, using Bruker timsTOF Pro 2, measures over 11,000 circulating small-molecule biomarkers in under a minute. The integrated discovery pipeline enables rapid biomarker discovery and cross-validation across diverse populations.